Equities

ImpediMed Ltd

ImpediMed Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.054
  • Today's Change0.001 / 1.89%
  • Shares traded2.29m
  • 1 Year change-60.00%
  • Beta2.7151
Data delayed at least 20 minutes, as of Nov 18 2024 04:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ImpediMed Limited is an Australia-based medical technology company. The Company uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The Company designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. SOZO uses its BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.

  • Revenue in AUD (TTM)10.32m
  • Net income in AUD-19.79m
  • Incorporated1999
  • Employees83.00
  • Location
    ImpediMed LtdPinkenba, U 1 50 Parker CtBRISBANE 4008AustraliaAUS
  • Phone+61 73860-3700
  • Fax+61 73260-1225
  • Websitehttps://www.impedimed.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Somnomed Ltd91.68m-12.24m62.67m300.00--0.8589--0.6836-0.1014-0.10140.75950.33761.397.037.81---18.51-8.96-26.05-13.3260.1760.40-13.35-7.081.45-2.790.1299--9.649.25-55.61--26.29--
Mach7 Technologies Ltd30.01m-7.97m89.26m90.00--1.72--2.97-0.0331-0.03310.12460.2150.3864--3.64---10.26-6.48-12.71-7.5695.1994.91-26.56-17.84---55.080.0239---1.4626.28-660.45--33.06--
Austco Healthcare Ltd58.15m7.08m91.93m174.0011.222.059.831.580.02250.02250.18850.1231.092.564.59--13.2910.5818.4215.0952.7453.6512.178.701.7538.420.1483--38.2812.84213.3761.8623.85--
ImpediMed Ltd10.32m-19.79m107.25m83.00--2.63--10.39-0.0098-0.00980.00510.02010.17831.674.28124,325.30-34.20-44.56-37.62-51.7887.2783.08-191.78-220.516.16--0.0273---9.0419.953.56--6.90--
Respiri Ltd1.04m-7.13m117.48m2.00--39.57--113.12-0.007-0.0070.0010.00230.22160.0026.91---152.14-153.06-384.52-255.3469.98---686.48-617.730.3744-108.650.0423--56.850.1379-23.44------
SDI Ltd111.21m10.42m127.78m300.0012.261.368.751.150.08770.08770.93560.79060.81181.555.51--7.617.139.328.4062.0859.869.378.191.408.010.208746.683.116.9247.697.2911.964.72
EchoIQ Ltd44.50k-5.41m132.42m----17.87--2,975.67-0.0109-0.01090.000090.01260.0048--0.1208---58.04-65.22-76.45-83.27-----12,155.39-1,722.30----0.00---58.54-44.2334.56------
Optiscan Imaging Ltd1.16m-6.06m142.01m8.00--10.24--122.89-0.0074-0.00740.00140.01660.11380.30620.9086---59.70-49.52-70.78-58.8454.4616.53-524.45-312.657.45--0.0157---31.221.91-39.27--80.89--
Orthocell Ltd6.76m-7.18m149.45m----28.86--22.09-0.0356-0.03560.03350.02170.24061.479.37---25.55-28.99-30.96-34.0275.9571.10-106.16-242.964.11--0.1321--32.7947.88-14.93--20.63--
Cyclopharm Limited29.04m-9.32m150.59m87.00--3.17--5.19-0.0976-0.09760.30660.42780.51211.114.01333,756.60-16.43-12.60-19.97-14.9464.7770.20-32.08-25.473.42-37.570.1049--11.2215.5028.90---7.83-12.94
Genetic Signatures Ltd14.27m-17.86m156.54m----2.43--10.97-0.1124-0.11240.08640.28380.24531.023.20---30.70-11.57-34.00-12.6944.5655.89-125.15-25.418.76-509.340.0196---35.2914.72-27.11--50.98--
Data as of Nov 18 2024. Currency figures normalised to ImpediMed Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

14.06%Per cent of shares held by top holders
HolderShares% Held
Paradice Investment Management Pty Ltd.as of 02 Aug 2024144.30m7.13%
Australian Ethical Investments Ltd. (Investment Management)as of 02 Aug 2024122.51m6.06%
First Samuel Ltd.as of 02 Aug 202415.28m0.76%
DFA Australia Ltd.as of 30 Sep 20241.60m0.08%
Dimensional Fund Advisors LPas of 07 Nov 2024758.39k0.04%
North Star Asset Management, Inc.as of 30 Sep 202420.00k0.00%
Dimensional Fund Advisors Ltd.as of 07 Nov 2024656.000.00%
Seven Canyons Advisors LLCas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 12 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.